Drug Profile
Apixaban oral film - TAHO Pharmaceuticals
Alternative Names: Anti-Thrombotic oral film - TAHO Pharmaceuticals; Anticoagulant oral film - TAHO Pharmaceuticals; TAH-3311Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator TAHO Pharmaceuticals
- Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules; Vascular disorder therapies
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Stroke
- Phase 0 Deep vein thrombosis; Pulmonary embolism
Most Recent Events
- 22 Aug 2023 TAHO Pharmaceuticals completes the early phase I trial in Deep vein thrombosis (prevention) in USA (NCT05995119)
- 24 May 2023 Chemical structure information added
- 13 Jan 2023 TAHO Pharmaceuticals completes the early phase I trial in Stroke (prevention) in USA (NCT05995119)